Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared on X:
“Staging kidney cancer with FDG PET has never really worked. A tracer aimed at CAIX, the antigen clear cell RCC almost always expresses, just showed why a target-specific approach fits the biology better.
Prospective single-center trial, 61 patients. Investigational CAIX tracer [18F]AlF-NYM005 vs [18F]FDG, head-to-head within one week, 331 lesions scored against a composite reference standard.
What stood out:
- Renal tumor accuracy 82.9% vs 42.9% for FDG (sensitivity 82% vs 43%)
- Metastatic detection: 248 vs 156 lesions, strongest in nodes, pleura/peritoneum, and lung
- Staging or restaging changed in 1/3 patients
CAIX was intermediate to strong in two-thirds of samples and tracked with uptake, stage, and grade. The tracer reads real tumor biology. FDG reads glucose avidity, which clear cell RCC often lacks.
Single-center, retrospectively registered, small and early. But nearly doubling diagnostic accuracy over FDG is hard to ignore.”
Title: CAIX-targeted PET/CT in the evaluation of clear cell renal cell carcinoma: a head-to-head comparison with [18F]FDG PET/CT
Authors: Wei Guo, Liang Cheng, Xinglu Zhou, Yue Zhao, Hui Chen, Yubai Zhang, Yudie Qin, Wei Liu, Geng Hu, Xinyue Yang, Huihui You, Wenyi Wei, Dayong Hou, Hao Jiang, Kezheng Wang.
Other articles about GU Oncology on OncoDaily.
